Trial Profile
Physiologic Effects of Long-Term GHRH1-44 in Abdominal Obesity
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Tesamorelin (Primary)
- Indications Obesity
- Focus Pharmacodynamics
- 07 Nov 2012 Status changed from active, no longer recruiting to completed.
- 26 Sep 2012 Results published in the Journal of Clinical Endocrinology and Metabolism.
- 27 Jun 2012 Primary endpoint 'Visceral-adipose tissue' has been met.